Business Wire

THALES

21.9.2022 10:09:38 CEST | Business Wire | Press release

Share
Confidence in Addressing Security Challenges of Hybrid Work Improving Among Businesses, Finds Thales

With the past two years resulting in a permanently altered working environment, changes in security were both necessary and notable. Controlling access to applications, data, and systems is an increasingly important aspect of securing any environment and protecting it against both internal and external threats.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220921005005/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

©Thales

After two years of the pandemic, confidence in addressing certain security risks and threats arising from hybrid and remote work has improved among businesses and organizations around the world. When it comes to secure access to applications, data, and systems, 84% IT professionals this year said they have some degree of confidence in their current user access security systems to enable remote work securely and easily, compared to 56% in 2021. In addition, 60% said this year they were highly confident compared to just 22% last year.

These are among some of the key findings from the 2022 Thales Access Management Index, a global survey of 2,600 IT decision makers, conducted by 451 Research, part of S&P Global Market Intelligence.

Firms Gaining Confidence Addressing Security of Remote Work
Overall, the report findings suggest that firms remain concerned about the security risks of remote work, but those concerns seem to be less severe. At the same time, firms are also growing more confident in the ability of authentication and access management systems to manage those risks. Only 31% of IT professional surveyed reported having “very high” concerns about the security risks and threats of remote work in 2022, down from 39% in 2021, while those who said they were “somewhat concerned” – the most popular response – increased from 43% to 48% in 2022.

Multi-Factor Authentication on the Rise But Not Widespread
While multi-factor authentication (MFA) usage remains most prevalent for remote workers (68%) and privileged users (52%), the report shows that MFA adoption is on the rise for internal and non-IT staff with MFA adoption increasing to 40% compared to 34% in 2021. However, widespread MFA adoption by businesses is still yet to be the norm with just over half (56%) have adopted MFA in their organizations.

Lingering Effects of Pandemic Drive Interest in Access Management, MFA and ZTNA
The survey inquired about direct impacts that the pandemic and remote work had on deployment plans for new access security technologies. Responses revealed a six-percentage-point global increase in plans to deploy stand-alone MFA, up from 31% in 2021. The pandemic also impacted plans to deploy cloud-based access management, selected by 45% of respondents worldwide compared to 41% in 2021. These two increases illustrate respondents’ growing awareness that threats come from all angles, and that proper authentication and management of access and privileges is necessary for an adequate security foundation. Last year, Zero Trust Network Access/Software-Defined Perimeter (ZTNA)/(SDP) was the top choice, selected by 44% of respondents. In 2022, ZTNA was the second choice at 42%.

Francois Lasnier, Vice President of Access Management Solutions at Thales comments: “The past few years have cemented remote work and work-from-anywhere as a permanent part of the security landscape, and they have also introduced new security risks and challenges. However, growing familiarity with remote work has ultimately broadened awareness on an enterprise level of daily business security risks and has strengthened both confidence and ability in security teams and products to handle those risks and threats properly.”

Garrett Bekker, Principal Analyst at 451 Research comments: “Just as the threat landscape has evolved, the tools and methods to handle the landscape have, too. However, even with innovative tools and boosted confidence levels, security plans and approaches still need to adapt to the ever-changing threat environment. A greater shift towards a Zero Trust model would place access management in a central role in corporate security strategies, with a related reliance on MFA as a critical supporting enabler.”

Thales and 451 Research will discuss the findings in more detail during a webinar on 29 September 2022. To join, please visit the registration page.

About the 2022 Thales Access Management Index
As organizations step beyond the urgent actions of the last two years, they’re grappling with securing the more complex environments in which they now operate. The global edition of the 2022 Thales Access Management Index looked at various aspects of those impacts in a wide-ranging survey of security professionals and executive leadership that touched on issues including access management and access security, multi-factor authentication, zero-trust network access, security spending plans, remote work and VPNs, and ransomware. The 2022 Thales Access Management Study is based on data from a survey of nearly 2,800 security professionals and executive leaders in more than 15 countries across the globe. This research was conducted as an observational study and makes no causal claims.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organizations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.

PLEASE VISIT

Thales Group
Security

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005005/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye